• Something wrong with this record ?

Difference in Serum Endostatin Levels in Diabetic Patients with Critical Limb Ischemia Treated by Autologous Cell Therapy or Percutaneous Transluminal Angioplasty

A. Nemcova, A. Jirkovska, M. Dubsky, L. Kolesar, R. Bem, V. Fejfarova, A. Pysna, V. Woskova, J. Skibova, EB. Jude,

. 2018 ; 27 (9) : 1368-1374. [pub] 20180604

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19035203

Grant support
NV16-27262A MZ0 CEP Register

The aim of this study was to compare the serum levels of the anti-angiogenic factor endostatin (S-endostatin) as a potential marker of vasculogenesis after autologous cell therapy (ACT) versus percutaneous transluminal angioplasty (PTA) in diabetic patients with critical limb ischemia (CLI). A total of 25 diabetic patients with CLI treated in our foot clinic during the period 2008-2014 with ACT generating potential vasculogenesis were consecutively included in the study; 14 diabetic patients with CLI who underwent PTA during the same period were included in a control group in which no vasculogenesis had occurred. S-endostatin was measured before revascularization and at 1, 3, and 6 months after the procedure. The effect of ACT and PTA on tissue ischemia was confirmed by transcutaneous oxygen pressure (TcPO2) measurement at the same intervals. While S-endostatin levels increased significantly at 1 and 3 months after ACT (both P < 0.001), no significant change of S-endostatin after PTA was observed. Elevation of S-endostatin levels significantly correlated with an increase in TcPO2 at 1 month after ACT ( r = 0.557; P < 0.001). Our study showed that endostatin might be a potential marker of vasculogenesis because of its significant increase after ACT in diabetic patients with CLI in contrast to those undergoing PTA. This increase may be a sign of a protective feedback mechanism of this anti-angiogenic factor.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035203
003      
CZ-PrNML
005      
20191014091641.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/0963689718775628 $2 doi
035    __
$a (PubMed)29860903
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nemcova, Andrea $u 1 Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Difference in Serum Endostatin Levels in Diabetic Patients with Critical Limb Ischemia Treated by Autologous Cell Therapy or Percutaneous Transluminal Angioplasty / $c A. Nemcova, A. Jirkovska, M. Dubsky, L. Kolesar, R. Bem, V. Fejfarova, A. Pysna, V. Woskova, J. Skibova, EB. Jude,
520    9_
$a The aim of this study was to compare the serum levels of the anti-angiogenic factor endostatin (S-endostatin) as a potential marker of vasculogenesis after autologous cell therapy (ACT) versus percutaneous transluminal angioplasty (PTA) in diabetic patients with critical limb ischemia (CLI). A total of 25 diabetic patients with CLI treated in our foot clinic during the period 2008-2014 with ACT generating potential vasculogenesis were consecutively included in the study; 14 diabetic patients with CLI who underwent PTA during the same period were included in a control group in which no vasculogenesis had occurred. S-endostatin was measured before revascularization and at 1, 3, and 6 months after the procedure. The effect of ACT and PTA on tissue ischemia was confirmed by transcutaneous oxygen pressure (TcPO2) measurement at the same intervals. While S-endostatin levels increased significantly at 1 and 3 months after ACT (both P < 0.001), no significant change of S-endostatin after PTA was observed. Elevation of S-endostatin levels significantly correlated with an increase in TcPO2 at 1 month after ACT ( r = 0.557; P < 0.001). Our study showed that endostatin might be a potential marker of vasculogenesis because of its significant increase after ACT in diabetic patients with CLI in contrast to those undergoing PTA. This increase may be a sign of a protective feedback mechanism of this anti-angiogenic factor.
650    _2
$a senioři $7 D000368
650    12
$a angioplastika $7 D017130
650    _2
$a antigeny CD34 $x analýza $7 D018952
650    _2
$a buněčná a tkáňová terapie $7 D064987
650    _2
$a diabetes mellitus 2. typu $x krev $x komplikace $7 D003924
650    _2
$a diabetická noha $x krev $x terapie $7 D017719
650    _2
$a endostatiny $x krev $7 D043169
650    _2
$a končetiny $x krevní zásobení $7 D005121
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a ischemie $x krev $x terapie $7 D007511
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fyziologická neovaskularizace $7 D018919
650    _2
$a onemocnění periferních cév $x terapie $7 D016491
650    12
$a transplantace kmenových buněk $7 D033581
650    _2
$a kmenové buňky $x cytologie $7 D013234
650    _2
$a autologní transplantace $7 D014182
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jirkovska, Alexandra $u 1 Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Dubsky, Michal $u 1 Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kolesar, Libor $u 2 Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Bem, Robert $u 1 Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Fejfarova, Vladimira $u 1 Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Pysna, Anna $u 1 Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Woskova, Veronika $u 1 Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Skibova, Jelena $u 1 Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Jude, Edward B $u 3 Diabetes Centre, Tameside Hospital NHS Foundation Trust and University of Manchester, Lancashire, UK.
773    0_
$w MED00001075 $t Cell transplantation $x 1555-3892 $g Roč. 27, č. 9 (2018), s. 1368-1374
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29860903 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014092105 $b ABA008
999    __
$a ok $b bmc $g 1451863 $s 1073753
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 27 $c 9 $d 1368-1374 $e 20180604 $i 1555-3892 $m Cell transplantation $n Cell Transplant $x MED00001075
GRA    __
$a NV16-27262A $p MZ0
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options